+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Down Syndrome - Pipeline Review, H1 2020

  • ID: 4911676
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 80 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AC Immune SA
  • Aelis Farma SAS
  • Annovis Bio Inc
  • Balance Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • ManRos Therapeutics
  • MORE
Down Syndrome - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Pipeline Review, H1 2020, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape.

Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes, unusual for the child's ethnic group and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers and excessive flexibility.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Down Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 4, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AC Immune SA
  • Aelis Farma SAS
  • Annovis Bio Inc
  • Balance Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • ManRos Therapeutics
  • MORE
  • Introduction
  • Report Coverage
  • Down Syndrome - Overview
  • Down Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Down Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Down Syndrome - Companies Involved in Therapeutics Development
  • AC Immune SA
  • Advanced Medical Projects
  • Aelis Farma SAS
  • Alzheon Inc
  • Annovis Bio Inc
  • Avanti Biosciences Inc
  • Balance Therapeutics Inc
  • Eisai Co Ltd
  • Elixirgen Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • KinoPharma Inc
  • ManRos Therapeutics
  • NeuroCircuit Therapeutics Inc
  • NeuroNascent Inc
  • San Biotechnology Co Ltd
  • Down Syndrome - Drug Profiles
  • ABI-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACI-24 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Down Syndrome - Dormant Projects
  • Down Syndrome - Discontinued Products
  • Down Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Down Syndrome, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Down Syndrome - Pipeline by AC Immune SA, H1 2020
  • Down Syndrome - Pipeline by Advanced Medical Projects, H1 2020
  • Down Syndrome - Pipeline by Aelis Farma SAS, H1 2020
  • Down Syndrome - Pipeline by Alzheon Inc, H1 2020
  • Down Syndrome - Pipeline by Annovis Bio Inc, H1 2020
  • Down Syndrome - Pipeline by Avanti Biosciences Inc, H1 2020
  • Down Syndrome - Pipeline by Balance Therapeutics Inc, H1 2020
  • Down Syndrome - Pipeline by Eisai Co Ltd, H1 2020
  • Down Syndrome - Pipeline by Elixirgen Therapeutics LLC, H1 2020
  • Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Down Syndrome - Pipeline by KinoPharma Inc, H1 2020
  • Down Syndrome - Pipeline by ManRos Therapeutics, H1 2020
  • Down Syndrome - Pipeline by NeuroCircuit Therapeutics Inc, H1 2020
  • Down Syndrome - Pipeline by NeuroNascent Inc, H1 2020
  • Down Syndrome - Pipeline by San Biotechnology Co Ltd, H1 2020
  • Down Syndrome - Dormant Projects, H1 2020
  • Down Syndrome - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Down Syndrome, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AC Immune SA
  • Advanced Medical Projects
  • Aelis Farma SAS
  • Alzheon Inc
  • Annovis Bio Inc
  • Avanti Biosciences Inc
  • Balance Therapeutics Inc
  • Eisai Co Ltd
  • Elixirgen Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • KinoPharma Inc
  • ManRos Therapeutics
  • NeuroCircuit Therapeutics Inc
  • NeuroNascent Inc
  • San Biotechnology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll